Halozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

SAN DIEGO, May 24, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the completion of its previously announced underwritten public offering of 11,500,000 shares of its common stock. The offering included 1,500,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. All shares in the offering were sold by Halozyme at a public offering price of $12.50 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, were approximately $135 million.

Halozyme intends to use the net proceeds from this offering to fund continued development of its PEGPH20 oncology program and for other general corporate purposes.

Wells Fargo Securities, LLC and Deutsche Bank Securities acted as joint book-running managers for the offering. Barclays and JMP Securities acted as co-managers for the offering.

An automatic shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by telephone at (800) 326-5897 or email to [email protected]; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005, or by telephone at (800) 503-4611 or email to [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the website of the SEC at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment.

Safe Harbor Statement
All of the statements in this press release that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include Halozyme's intended use of proceeds. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. A discussion of the risks and uncertainties that can affect these statements is set forth in Halozyme's prospectus supplement and the accompanying prospectus filed with the SEC on May 19, 2017, together with the information incorporated by reference, under the heading "Risk Factors."  Halozyme disclaims any intention or obligation to revise or update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
Jim Mazzola
858-704-8122
[email protected]

Chris Burton
858-704-8352
[email protected]

SOURCE Halozyme Therapeutics, Inc.